Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15742795 | 0.80 | NOTUM (0.41) | NOTUM | |
| SCHEMBL225527 | 0.73 | TSHR (0.33) | — | |
| SCHEMBL15742912 | 0.70 | NOTUM (0.34) | NOTUM | |
| SCHEMBL11882799 | 0.69 | — | — | |
| SCHEMBL224657 | 0.69 | — | — | |
| SCHEMBL760452 | 0.68 | — | — | |
| SCHEMBL1967064 | 0.68 | — | — | |
| SCHEMBL10582834 | 0.68 | NOTUM (0.42) | NOTUM | |
| SCHEMBL6222544 | 0.68 | NOTUM (0.42) | NOTUM | |
| SCHEMBL2363028 | 0.67 | RXRA (0.38) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | claimed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | claimed |
| US-5258523-A | Process for the production of 2-aryl-2H-1,2,3-triazoles | LONZA LTD. (CH) | 1993-11-02 | — | — | US | claimed |
| US-4512989-A | IMIDOESTERS OR IMIDOTHIOESTERS | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 1985-04-23 | — | — | US | claimed |
| US-4060623-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | claimed |
| US-4038404-A | 1,2,4-TRIAZOLE ANTIMYCOTIC COMPOSITIONS AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | claimed |
| US-4036967-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | claimed |
| US-4036966-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | claimed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-2922831-B1 | PESTICIDAL COMPOUNDS BASED ON ARYLTHIOSULFONAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9686988-B2 | Pesticidal compounds based on arylthiosulfonamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9675073-B2 | Insecticidal compounds based on N-arylsulfanylmethylcarboxamidearylthiosulfonamides derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-13 | — | — | US | disclosed |
| EP-2334683-B1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | MSD ITALIA SRL (IT) | 2017-03-22 | — | — | EP | disclosed |
| EP-3093284-A1 | ETHEREAL OXYGEN-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | Asahi Glass Company, Limited (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-4060623-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4038404-A | 1,2,4-TRIAZOLE ANTIMYCOTIC COMPOSITIONS AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
| US-4038406-A | 1,2,4-TRIAZOLE ANTIMYCOTIC COMPOSITIONS AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
| US-4036966-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-4036967-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-4002763-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NOTUM 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.